Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730146 | 0.84 | RAB9A (0.56) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL15723899 | 0.82 | PANK3 (0.51) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6666475 | 0.76 | HTR2C (0.60) | RAB9ANPC1KMT2A | |
| SCHEMBL8361622 | 0.73 | RAB9A (0.97) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL20371541 | 0.71 | CNR2 (0.56) | KDM4E | |
| SCHEMBL17066911 | 0.70 | MKNK1 (0.51) | — | |
| SCHEMBL20371667 | 0.70 | IKBKB (0.48) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL20371520 | 0.70 | MKNK1 (0.66) | — | |
| SCHEMBL12844141 | 0.70 | LMNA (0.53) | NPC1KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL20371609 | 0.68 | SYK (0.46) | RAB9ANPC1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | RAB9A 357/4885NPC1 2/4885KMT2A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.